BOSTON & PERTH, Australia & ATLANTA--(BUSINESS WIRE)--June 7, 2006--Global bio-nanotech company pSivida Limited (ASX:PSD - News; Nasdaq:PSDV - News; Xetra:PSI - News) and development partner Alimera Sciences Inc., today announced that regulatory agencies in the U.K., Canada and India have approved the commencement of Phase III clinical trials of the Medidur(TM) device for the treatment of diabetic macular edema (DME). These international clinical sites are opening in conjunction with the sites already underway in the U.S. The Medidur development plan has already been granted Fast Track status in the U.S. by the Food and Drug Administration (FDA).
